Whitehawk Therapeutics, Inc. WHWK
3.02 USD -0.15 (-4.73%)
At closeNov 5, 2026, 4:02 PM EST
3.03 +0.01 +0.33%
After hours · Nov 5, 4:02 PM ET
2.91 Day range 3.16
1.97 52-week range 5.50
- YTD
- +24.79%
- 1 year
- +34.22%
- Market cap
- 172.17M
- EPS (ttm)
- -1.14
- YTD return
- +24.79%
- 1-year return
- +34.22%
- Volume
- 705.28K
- Avg volume
- 341.78K
- Open
- 3.16
- Previous close
- 3.17
- Day's range
- 2.91 – 3.16
- 52-week range
- 1.97 – 5.50
1M -0.58 (-16.07%)
Financials — quick view
WHWK Revenue — quarterly 0
WHWK Net income — quarterly -16.64M
WHWK EPS — quarterly -0.20
News
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison 
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages 
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16 
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9 
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20 
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC 
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Your note
Sign in to keep a note on WHWK — it syncs with the Stock Master app.